AU2005224597A1 - Cytotoxicity assay - Google Patents

Cytotoxicity assay Download PDF

Info

Publication number
AU2005224597A1
AU2005224597A1 AU2005224597A AU2005224597A AU2005224597A1 AU 2005224597 A1 AU2005224597 A1 AU 2005224597A1 AU 2005224597 A AU2005224597 A AU 2005224597A AU 2005224597 A AU2005224597 A AU 2005224597A AU 2005224597 A1 AU2005224597 A1 AU 2005224597A1
Authority
AU
Australia
Prior art keywords
cells
caspase
assay
cell
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005224597A
Other languages
English (en)
Inventor
Pamela Dunn
Liwei He
Laszlo Radvanyi
Danielle Salha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Inc
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of AU2005224597A1 publication Critical patent/AU2005224597A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
AU2005224597A 2004-01-23 2005-01-21 Cytotoxicity assay Abandoned AU2005224597A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53899304P 2004-01-23 2004-01-23
US60/538,993 2004-01-23
PCT/US2005/001993 WO2005090990A2 (en) 2004-01-23 2005-01-21 Cytotoxicity assay

Publications (1)

Publication Number Publication Date
AU2005224597A1 true AU2005224597A1 (en) 2005-09-29

Family

ID=34966212

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005224597A Abandoned AU2005224597A1 (en) 2004-01-23 2005-01-21 Cytotoxicity assay

Country Status (11)

Country Link
EP (1) EP1706744A2 (es)
JP (1) JP2007522447A (es)
KR (1) KR20070001930A (es)
CN (1) CN101065669A (es)
AU (1) AU2005224597A1 (es)
BR (1) BRPI0506488A (es)
CA (1) CA2559394A1 (es)
IL (1) IL176938A0 (es)
MX (1) MXPA06008336A (es)
WO (1) WO2005090990A2 (es)
ZA (1) ZA200605715B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013126720A2 (en) * 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Compositions and methods for the assessment of target cancer cell resistance to car engineered t cell killing
TWI750110B (zh) 2014-07-21 2021-12-21 瑞士商諾華公司 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
AU2015292811B2 (en) 2014-07-21 2019-12-19 Novartis Ag Treatment of cancer using a CLL-1 chimeric antigen receptor
JP6604975B2 (ja) * 2015-02-09 2019-11-13 株式会社ライフアートビレッジ 免疫細胞療法のためのペプチドスクリーニング方法
CN105547971B (zh) * 2016-01-08 2018-05-01 首都医科大学附属北京友谊医院 细胞毒性t细胞脱颗粒的流式细胞术检测方法
CN105445171B (zh) * 2016-01-08 2018-03-02 首都医科大学附属北京友谊医院 自然杀伤细胞脱颗粒的流式细胞术检测方法
KR20210020932A (ko) 2018-06-13 2021-02-24 노파르티스 아게 Bcma 키메라 항원 수용체 및 이의 용도
WO2023103785A1 (en) * 2021-12-06 2023-06-15 Wuxi Biologics (Shanghai) Co., Ltd. 3d bioassays to measure antibody-dependent cell-mediated cytotoxicity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211548A1 (en) * 2002-01-29 2003-11-13 Oncolmmunin, Inc. Visualization and quantitiation of cellular cytotoxicity using cell-permeable fluorogenic protease substrates and caspase activity indicator markers
US20070154464A1 (en) * 2003-11-14 2007-07-05 Jerome Keith R Methods for screening for agents capable of modulating t lymphocyte function in response to a herpes simplex virus-infected cell

Also Published As

Publication number Publication date
CA2559394A1 (en) 2005-09-29
WO2005090990A2 (en) 2005-09-29
IL176938A0 (en) 2006-12-10
JP2007522447A (ja) 2007-08-09
BRPI0506488A (pt) 2007-02-13
EP1706744A2 (en) 2006-10-04
WO2005090990A3 (en) 2007-01-11
ZA200605715B (en) 2007-04-25
CN101065669A (zh) 2007-10-31
MXPA06008336A (es) 2007-04-17
KR20070001930A (ko) 2007-01-04

Similar Documents

Publication Publication Date Title
He et al. A sensitive flow cytometry-based cytotoxic T-lymphocyte assay through detection of cleaved caspase 3 in target cells
Herr et al. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor α in response to HLA-A2. 1-binding melanoma and viral peptide antigens
Clay et al. Assays for monitoring cellular immune responses to active immunotherapy of cancer
AU2005224597A1 (en) Cytotoxicity assay
Roberts et al. Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells
Tsuji et al. Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial
US20070087333A1 (en) Method to detect antigen-specific cytolytic activity
US7851591B1 (en) Cancer immunotherapy and diagnosis using universal tumor associated antigens, including hTERT
Yee et al. In vivo tracking of tumor-specific T cells
Kawashima et al. Identification of GP100‐derived, melanoma‐specific cytotoxic T‐lymphocyte epitopes restricted by HLA‐A3 supertype molecules by primary in vitro immunization with peptide‐pulsed dendritic cells
US20230184748A1 (en) Measuring frequency of pathogen-specific t cells in peripheral blood
Van Nuffel et al. Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens
Malyguine et al. New approaches for monitoring CTL activity in clinical trials
US20090202499A1 (en) Human Telomerase Reverse Transcriptase Peptides
US20060160153A1 (en) Method to measure a t cell response and its uses to qualify antigen-presenting cells
Walker et al. Monitoring immune responses in cancer patients receiving tumor vaccines
Knights et al. Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients
Lulu et al. Characteristics of immune memory and Effector activity to cancer-expressed MHC class I phosphopeptides differ in healthy donors and ovarian cancer patients
Xu et al. Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients
Hobeika et al. Quantitating therapeutically relevant T-cell responses to cancer vaccines
Mosca et al. Immune monitoring
Martin et al. Tools and methods for identification and analysis of rare antigen-specific T lymphocytes
Markovic et al. A reproducible method for the enumeration of functional (cytokine producing) versus non-functional peptide-specific cytotoxic T lymphocytes in human peripheral blood
Mäki Characterization of MHC-I restricted immunogenic peptides by immunological and in silico methods
EP2775301B1 (en) Indirect antigen-specific lymphocyte recognition assay

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application